Skip to content
i2E
  • Programs
    • E3
    • Bridge2
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • Bridge2
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

DormaTarg working to make impact on cancer

Get in Touch

By Scott Meacham
Copyright © 2014, The Oklahoma Publishing Company

Oklahoma is building a reputation nationwide as a place where discoveries in bioscience lead to groundbreaking solutions that can have a real impact on people’s lives.

One exciting example is DormaTarg, an Oklahoma-based firm that is developing therapeutics to deal with one of the toughest challenges in fighting cancer — inhibiting the recurrence in metastasis-prone cancers.

“We have a drug that we believe targets dormant cells before they reactivate and can prevent cancer from metastasizing — going from a primary to a secondary site,” said Michael Ihnat, DormaTarg’s director of drug development.

When tumors travel from the point of origin to some other part of the body, they frequently go dormant; they are hard to find and identify, even with current technology.

Further, even though the tumors aren’t actively growing, they are waiting until certain conditions allow them to reactivate, after which the cancer is likely to be stronger and more vicious than the primary tumor was.

The American Cancer Society reports that upwards of 90 percent of all cancer deaths resulting from cancer are attributable to metastasis.

The initial application of DormaTarg’s agent is for triple negative breast cancer (TNBC), which is so named because this metastasis-prone cancer lacks three essential targets for current therapy. TNBC accounts for about 15 percent to 25 percent of all breast cancer cases.

DormaTarg screened more than 15,000 compounds to develop the DT300 series of molecules. DT330 has prevented reactivation of metastatic cancer cells in pre-clinical trials and has been shown to be relatively nontoxic, water soluble, and compatible with current therapies.

This amazing science has the potential to help thousands of TNBC patients and eventually patients with other metastatic cancers as well.

But that’s just part of the DormaTarg story. The greatest science in the world can’t help patients until it reaches the marketplace.

The DormaTarg team of cancer specialists and entrepreneurs, with more than 40 years of experience in cancer research and drug development, is meeting the milestones that remove risk and prove efficacy.

DormaTarg has been primarily funded through the Small Business Innovation Research program and other sources of nondilutive capital, of more than $3 million, most of which came from the National Cancer Institute.

The firm has strategic partnerships with some of the best regulatory consultants, formulation experts, and intellectual property attorneys in the industry.

“TNBC is our best entry point to prove efficacy,” Ihnat said. “Our end game is to make a real difference on the aspect of cancer that kills millions of patients every year.”

Oklahoma’s bioscience sector’s economic activity already exceeds $6.7 billion with a return on the state’s investment through the Oklahoma Center for the Advancement of Science and Technology of better than 20-to-1.

It’s great to think that the relatively small investments we are making in biotechnology in Oklahoma may have such a fundamental, lifesaving impact on people around the globe someday.

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at [email protected].

Did You Know? Bioscience businesses in Oklahoma support more than 51,000 Oklahoma jobs and annual revenues of more than $4.1 billion.

Read it at newsok.com

 

  • admin
    admin

More News

Loading...
headshot of Meredith Wilkerson
Blog, i2E
02.15.23

i2E Spotlight: Meredith Wilkerson, Life Sciences Venture Advisor & OKBio Director

Read more
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2023 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram

Programs

  • E3
  • Bridge2
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E